source
- Roche's Genentech signs up to $2.3B deal with Hanmi for weight-loss drug that preserves lean massRoche, through its Genentech subsidiary, has entered a licensing agreement with South Korea's Hanmi Pharm that could be worth up to $2.3 billion, including a $190 million upfront payment. The deal…
- Roche to acquire Hanmi's lean-mass preserving obesity shot in $2.3 bn dealRoche announced a partnership with South Korean company Hanmi Pharm to obtain rights to a novel obesity drug outside South Korea. Under the agreement, Roche will pay $190 million upfront and could…